Welcome to our dedicated page for Tonix Pharmaceuticals Holding SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tonix Pharmaceuticals Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tonix Pharmaceuticals Holding's regulatory disclosures and financial reporting.
Tonix Pharmaceuticals Holding Corp. ownership update: Point72 group reports beneficial ownership of 1,100,964 shares of Common Stock, representing 6.9% of the class as of the close of business on May 14, 2026. The filing attributes shared voting and dispositive power across Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen.
A footnote states that as of March 31, 2026 the reporting persons may have been deemed to beneficially own 125,414 shares (representing 0.9% as of that date). The statement clarifies that the reporting persons directly own no shares and that Point72 Associates holds the referenced securities.
Tonix Pharmaceuticals reported Phase 1 results for TNX-4800, an investigational long-acting monoclonal antibody designed to prevent Lyme disease. In 44 healthy volunteers, single subcutaneous doses showed a favorable safety profile, mostly mild injection-site reactions, and dose‑proportional pharmacokinetics with a mean half‑life of about 62–69 days. Serum levels were detectable within two days and remained quantifiable for up to 12 months in most participants, with exposure at the highest 10 mg/kg dose under 17% of peak levels seen in rat toxicology. Nonclinical primate data support protective serum thresholds, and modeling underpins a two‑dose regimen. Tonix plans an adaptive Phase 2 field study in 2027, pending FDA agreement, while highlighting approximately $185.5 million in cash and no debt as of March 31, 2026.
Tonix Pharmaceuticals Holding Corp. reporting persons Sirenia Capital Management and Alex Silverstein disclose beneficial ownership of 1,297,470 shares of common stock, representing 8.8% of the class on an as‑converted basis. The percentage "assumes the exercise of the warrants" held by the Sirenia Fund.
The filing cites 14,205,401 shares outstanding as of March 27, 2026 from the issuer's proxy statement and notes that 615,025 shares are issuable upon exercise of warrants included in the reported total.
Tonix Pharmaceuticals Holding Corp. director Richard Newcomb Stillwell received a stock option grant covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036. They were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. After this compensation award, Stillwell holds 22,700 derivative securities linked to common stock directly, with no open-market purchase or sale reported in this filing.
Tonix Pharmaceuticals Holding Corp. director Adeoye Y Olukotun reported receiving a stock option grant covering 22,700 shares of common stock. The option has an exercise price of $13.28 per share and expires on May 12, 2036. It was granted under the company’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Following this grant, Olukotun holds stock options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director Margaret Smith Bell received a grant of stock options as part of equity compensation. She was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, she holds derivative rights to 22,700 shares through these options, which expire in 2036.
Tonix Pharmaceuticals Holding Corp. director Hunter James Randolph Jr reported receiving a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, with no cash paid at grant.
The options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year from the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this grant, Randolph holds options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director James Treco received a grant of stock options as part of equity compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, expiring in 2036.
The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the May 12, 2026 grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, Treco holds options for 22,700 shares directly.
Tonix Pharmaceuticals Holding Corp. director David L. Grange received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share, vest on the earlier of one year from grant or the 2027 annual stockholders meeting, and expire in 2036.
Tonix Pharmaceuticals Holding Corp. director Richard H. Bagger received a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. These options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year after the grant date or the 2027 Annual Meeting of Stockholders. Following this award, he holds 22,700 derivative securities directly.